Newsletter del 15 ottobre 2014
SEGUICI SU
Direttore Editoriale: Gian Paolo Andreoletti, MD
Editoriale
"Mastectomia bilaterale e mortalità per carcinoma mammario"
"No evidence of lower mortality with bilateral mastectomy f...
rassegna stampa
Linee guida ESO-ESMO per la terapia del carcinoma mammario avanzato
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Terapia con tamoxifene e rischio di diabete mellito
Tamoxifen use in breast cancer patients might increase subsequent diabetes risk
Terapia antiandrogenica nel tumore mammario maschile metastatico
Antiandrogen therapy is effective in metastatic male breast cancer patients with androgen receptor-expressing tumors
Lo screening mammario nelle donne di 70-75 anni
The effect of screening program in women aged 70-75 years is limited and may lead to overdiagnosis
Allattamento e rischio di tumore al seno
Parous women who have not breastfed are at increased risk of ER- and triple-negative breast cancer
Uso di lassativi e rischio di tumore colorettale
Risk for colorectal cancer increases with non-fiber laxative use and decreases with fiber laxative use
Chemioterapia con derivati del platino in pazienti con metastasi polmonari da carcinoma mammario triplo-negativo
Platinum-based chemotherapy effective in first–line treatment of lung metastasis from triple-negative breast cancer
Biguanidi e carcinoma mammario
The biguanides metformin and phenformin inhibit angiogenesis and local/metastatic growth of breast cancer
Inibizione combinata di BRAF e MEK nella terapia del melanoma metastatico
Combination of inhibitors to BRAF and MEK improves survival among patients with metastatic melanoma
FOLFOX adiuvante nel carcinoma rettale localmente avanzato
Adjuvant FOLFOX improves survival compared with fluorouracil plus leucovorin in locally advanced rectal cancer
Trattamento conservativo del tumore renale in fase iniziale
Percutaneous ablation and partial nephrectomy for cT1 renal masses have comparable rates of local recurrence
Combinazione di erlotinib e bevacizumab nel tumore polmonare non a piccole cellule positivo per mutazione EGFR
Erlotinib plus bevacizumab combination could be a first-line regimen in EGFR mutation-positive non-small-cell lung cancer
Alopecia e rischio di neoplasia della prostata
Frontal plus moderate vertex baldness at age 45 years is linked to increased risk of aggressive prostate cancer
eventi
Late and later relapses and sequelae: the dilemma of endocrine treatment duration, compliance and treatment tailoring
10th Meet the Professor. Advanced International Breast Cancer Conference (AIBCC) - con il Patrocinio di Senology
The data in our possesion is done in according with law 675/96.
If this e-mail has reached you in error, simply click on the following link and unsubscribe yourself.
Copyright 2010 A&B Snc Edizioni Medico Scientifiche. All rights reserved. P.Iva 02307560169
SUBSCRIBE | UNSUBSCRIBE | CONTATTI